Study on the Source of Increased Plasminogen Activators (tPA, uPA) and their inhibitors (PAI-1, PAI-2) in Pregnancy Plasma

We measured the plasma levels of plasminogen activators (tPA, uPA) and their inhibitors (PAI-1, PAI-2) at various intervals during pregnancy, delivery and puerperium. Their antigens were measured by Biopool Tint Elize Kits. In the pregnancy plasma of the third trimester, the levels of the activators were about 2 times and those of their inhibitors were about 10 times higher than those in non-pregnancy plasma.To clarify whether the uterus and/or placenta are involved in the increased levels of plasma PA and their inhibitors, their levels were measured in the retroplacental blood (RPB) and the uterine venous blood (UVB). The level of tPA in the RPB was the same as that in the peripheral venous blood (PVB) but the levels of uPA, PAI-1 and PAI-2 in the RPB was about 2.5 times higher than those in the PVB. During the ante-partum period, only the level of uPA in the UVB was higher than that in the PVB, while there was no significant difference between the levels of tPA, PAI-1 and PAI-2 in the PVB and UVB. The level of tPA in the UVB rose after separation of placenta. In contrast, the level of uPA declined immediately after the separation. There was no significant difference between the levels of PAI-1 and PAI-2 in the UVB before and after removal of the placenta.The release of tPA from endotherial cell was enhanced in vitro by addition of the pregnancy plasmas obtained at the time of delivery.These results suggest that placenta, uterus and entire vascular system are involved in the increase of tPA and uPA during pregnancy but that the major source of their inhibitors in the pregnancy plasma are unknown.

[1]  C. Reilly,et al.  The pharmacokinetics of plasminogen activator inhibitor-1 in the rabbit. , 1990, Blood.

[2]  Y. Takada,et al.  Source of increased plasminogen activators during pregnancy and puerperium. , 1989, Thrombosis research.

[3]  E. Kruithof,et al.  Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. , 1987, Blood.

[4]  C. Kluft,et al.  Plasminogen activator inhibitors. , 1987, Blood.

[5]  I. Hägerstrand,et al.  Cellular Localisation in Placenta of Placental Type Plasminogen Activator Inhibitor , 1986, Thrombosis and Haemostasis.

[6]  J. Zeuthen,et al.  Immunological Relationship Between the Fast-Acting Plasminogen Activator Inhibitors from Plasma, Blood Platelets and Endothelial Cells Demonstrated with a Monoclonal Antibody Against an Inhibitor from Placenta , 1986, Thrombosis and Haemostasis.

[7]  H. Chapman,et al.  Characterization of a macrophage-derived plasminogen-activator inhibitor. Similarities with placental urokinase inhibitor. , 1985, Biochemical Journal.

[8]  A. Lundblad,et al.  Purification of a Specific Placental Plasminogen Activator Inhibitor by Monoclonal Antibody and Its Complex Formation with Plasminogen Activator , 1985, Thrombosis and Haemostasis.

[9]  A. Vaheri,et al.  Urokinase‐type plasminogen activator and its inhibitor secreted by cultured human monocyte‐macrophages , 1985, Journal of cellular physiology.

[10]  D. Lawrence,et al.  Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. , 1984, The Journal of biological chemistry.

[11]  E. Jaffe,et al.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. , 1973, The Journal of clinical investigation.

[12]  T. Kawano,et al.  Urokinase Inhibitor in Human Placenta , 1968, Nature.